Application of sodium houttuyfonate in preparing medicament for preventing and treating myocardial hypertrophy and/or ventricular hypertrophy

A technology of houttuyfonate sodium and myocardial hypertrophy, which is applied in the direction of drug combination, pharmaceutical formula, cardiovascular system diseases, etc., to achieve the effect of preventing or heart failure, inhibiting activation, and having a large safety range

Inactive Publication Date: 2010-01-06
SHANGHAI UNIV OF T C M
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are no reports and applications of houttuynia cordata and houttuyniatin s

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sodium houttuyfonate in preparing medicament for preventing and treating myocardial hypertrophy and/or ventricular hypertrophy
  • Application of sodium houttuyfonate in preparing medicament for preventing and treating myocardial hypertrophy and/or ventricular hypertrophy
  • Application of sodium houttuyfonate in preparing medicament for preventing and treating myocardial hypertrophy and/or ventricular hypertrophy

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0018] Example 1: Experiment of houttuyfonate sodium against isoproterenol-induced ventricular hypertrophy in mice

[0019] 1.1 Experimental animals: Kunming mice, weighing 20-22g; purchased from Shanghai Experimental Animal Center of Chinese Academy of Sciences, and raised in SPF laboratory of Experimental Animal Center of Shanghai University of Traditional Chinese Medicine.

[0020] 1.2 Drugs and reagents: houttuyfonate sodium (batch number: 070103), product of Shanghai Qingping Pharmaceutical Co., Ltd.; isoproterenol hydrochloride injection (batch number: 5E20010), product of Shanghai Hefeng Pharmaceutical Co., Ltd.; metoprolol tartrate Er tablets (batch number: 0605002), a product of AstraZeneca Pharmaceutical Co., Ltd.

[0021] 1.3 Preparation of houttuyfonate sodium test solution: Weigh an appropriate amount of houttuyfonate sodium, dissolve it in warm water and ultrasonically before use, and prepare a solution with a concentration of 4.5 and 9 mg / ml.

[0022] 1.4 Experimental m...

Example Embodiment

[0039] Example 2: Experiment of the effect of sodium houttuyfonate against L-thyroxine sodium-induced ventricular hypertrophy in rats

[0040] 2.1 Experimental animals: SD rats, male, weighing 150-170g, purchased from the Shanghai Experimental Animal Center of the Chinese Academy of Sciences, and raised in the SPF animal laboratory of the Experimental Animal Center of Shanghai University of Traditional Chinese Medicine.

[0041] 2.2 Drugs and reagents: Houttuyfonate sodium (batch number: 070103) Shanghai Qingping Pharmaceutical Co., Ltd. product; L-thyroxine sodium (L-Thy, batch number: WA1331), Sigma company product; Captopril (Captopril, Lot number: 061005), product of Shanghai Hengshan Pharmaceutical Co., Ltd.; Endothelin (FT-1) kit (lot number: 070620), purchased from Beijing Northern Institute of Biotechnology; Hydroxyproline kit (lot number: 20070623), test Masbrillin protein determination kit (batch number: 20070515), purchased from Nanjing Jiancheng Reagent Company.

[0042]...

Example Embodiment

[0060] Example 3: Effect of sodium houttuyfonate against myocardial hypertrophy in rats with incomplete abdominal aorta ligation

[0061] 3.1 Experimental animals: SD rats, male, weighing 220-250g, purchased from the Shanghai Experimental Animal Center of the Chinese Academy of Sciences, and raised in the SPF animal laboratory of the Experimental Animal Center of Shanghai University of Traditional Chinese Medicine.

[0062] 3.2 Drugs and reagents: Houttuyfonate sodium (batch number: 0711-3), product of Shanghai Qingping Pharmaceutical Co., Ltd.; Captopril (Captopril, batch number: 070704), product of Shanghai Hengshan Pharmaceutical Co., Ltd.; angiotensin II kit (batch number: 20080420), aldosterone test kit (batch number: 20080420), tumor necrosis factor test kit (batch number: 20080530), all purchased from Beijing North Institute of Biotechnology; Coomassie brilliant blue protein assay kit (batch number) : 20070515), purchased from Nanjing Jiancheng Reagent Company.

[0063] 3.3 P...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses new application of sodium houttuyfonate in pharmacy, in particular to the application of the sodium houttuyfonate in preparing medicaments for preventing and treating myocardial hypertrophy and/or ventricular hypertrophy. The application is to prepare an in-vitro myocardial cell hypertrophyby adopting three methods of preparing an in-vivo animal model of myocardial hypertrophy and ventricular hypertrophy, culturing a myocardial cell in vitro and inducing epinephrine by isoproterenol, L-thyroxine and abdominal aorta banding. Experiment results prove that the sodium houttuyfonate can reduce the increase of left cardiac index and global cardiac index of a model animal, inhibit hypertrophy of an in-vitro myocardial cell, reduce the cAMP concentration of plasma, the content of Ang II and ET-1 of a myocardial tissue and the content of TNF-alpha and ALD of serum, and can reduce blood pressure and decrease heart rate. Experiment results suggest that the sodium houttuyfonate has the functions of resisting myocardial hypertrophy and ventricular hypertrophy, and the mechanism of the sodium houttuyfonate can be related to the inhibition of sympathetic activity, blockage of system activity of feritin-hypertensin-aldosterone, and effect of endocrine factors.

Description

technical field [0001] The invention belongs to the field of pharmacy and relates to the use of houttuyfonate sodium, an active ingredient of traditional Chinese medicine, in the preparation of medicines for preventing and treating myocardial hypertrophy and / or ventricular hypertrophy. Background technique [0002] Chronic cardiac insufficiency, also known as congestive heart failure (CHF), is a clinical syndrome in which the pumping function of the heart is reduced due to various etiologies and cannot discharge enough blood to meet the metabolic needs of tissues and organs throughout the body. The fatality rate is high. [0003] In the past, the clinical treatment of CHF focused on the use of cardiac glycosides with positive inotropic effects and diuretics. A large number of clinical data show that although all drugs that enhance myocardial contractility and improve hemodynamics can achieve a certain effect of improving symptoms in the short term, they cannot prevent ventr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/121A61P9/04
Inventor 高建平陈长勋
Owner SHANGHAI UNIV OF T C M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap